ImmunityBio revenue and financials
$9.69Change from previous close: −6.65%Absolute change: −$0.69
In the fiscal year ended December 2025, ImmunityBio reported revenue of $113.29M (+668.31% year over year). The net loss was $351.4M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +668.31%
- 2025 vs 2024
- Net margin
- -310.2%
- 2024: -2,804.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -66.5 | -75.4 | -70.4 | -68.9 | -79.7 | -85.9 | -85.1 | -98.8 | -100 | -107 | -115 | -87.4 |
| Depreciation and amortization | 4.4 | 4.4 | 3.8 | 4.0 | 3.9 | 3.8 | 4.1 | 4.5 | 4.4 | 4.6 | 4.6 | 4.6 |
| Capital expenditure | -3.5 | -1.8 | -0.9 | -0.7 | -1.1 | -1.1 | -2.1 | -2.8 | -0.7 | -1.3 | -8.0 | -5.7 |
| Investing cash flow | -107 | -31.7 | 43.6 | -181 | -16.1 | 4.1 | 9.8 | 65.0 | -51.5 | -35.6 | 2.2 | -15.6 |
| Financing cash flow | 44.4 | 224 | 54.9 | 174 | 173 | -1.0 | 107 | 15.6 | 149 | 10.2 | 201 | 238 |
| Dividends paid | — | — | — | — | — | 0.0 | — | — | — | — | — | — |
| Share repurchases | -0.3 | -7.0 | -0.6 | -0.2 | -0.3 | -1.2 | -0.8 | -0.3 | -0.5 | -3.9 | -1.6 | -1.5 |
| Debt issued | -0.1 | 75.1 | 2.9 | — | 0.0 | 0.0 | — | — | 97.0 | — | 193 | 199 |
| Debt repaid | -0.9 | -0.9 | -1.1 | -0.0 | -0.0 | — | — | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 |
| Effect of exchange rates | -0.0 | 0.1 | 0.0 | -0.1 | 0.1 | -0.0 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | -0.0 |
| Net change in cash | -130 | 117 | 28.1 | -76.8 | 77.0 | -82.8 | 31.6 | -18.1 | -2.9 | -132 | 87.5 | 134 |
| Free cash flow | -70.0 | -77.1 | -71.3 | -69.6 | -80.8 | -87.0 | -87.3 | -102 | -101 | -108 | -123 | -93.1 |
| Levered free cash flow | -48.5 | -43.7 | -43.8 | -50.6 | -55.6 | -63.3 | -58.3 | -72.0 | -58.1 | -67.9 | -90.8 | -56.9 |